FMO5 and coronary artery disorder: The G6PD-deficient phenotype can protect against coronary heart disease by inhibiting 3-hydroxy-3-methylglutarylcoenzyme A reductase (HMG-CoA R) activity and reducing NADPH oxidase activity [37–39].